Supporting information

Manuscript title: Subgrouping multimorbid patients with ischemic heart disease by means of unsupervised clustering: A cohort study of 72,249 patients defined by 3,046 diagnoses.

Authors: Haue AD, Holm PC, et al.



S1 Fig: Classification of new ischemic events. A: Time from index to first revascularization vs. percentage of patients revascularized. Blue corresponds to events related to establishment of IHD. Red corresponds to events considered new ischemic events. B: Time from index to first hospitalization for acute myocardial infarction vs. percentage of patients hospitalized. Blue corresponds to events related to index. Red corresponds to events considered new ischemic events. C: Distribution of days between revascularization for patients subjected to >1 performed >24 hours apart. Revascularizations performed <2 weeks apart were analyzed as a single event performed at date of the earliest revascularization. Marked by dashed line. IHD = ischemic heart disease.

S1 Table: Eligible codes for inclusion and outcomes

ICD-10[1] chapter IX			Definition, level 3
Block	**Level 3**	**Level 4**	
R94	I20	I20.0*, I20.1, I20.8, I20.9	Angina pectoris
	I21*	I21.0, I21.1, I21.2, I21.3, I21.4, I21.9	Acute myocardial infarction
	I23	I25.0, I25.1, I25.2, I25.23, I25.4, I25.5, I25.6, I25.8, I25.9	Certain current complications following acute myocardial infarction
	I24	I24.0, I24.1, I24.8, I24.9	Certain current complications following acute myocardial infarction
	I25	I25.0, I25.1, I25.2, I25.23, I25.4, I25.5, I25.6, I25.8, I25.9	Chronic ischaemic heart disease
NOMESCO[2] code		**Procedure**	
FNA*		Connection to coronary artery from internal mammary artery	
FNB*		Connection to coronary artery from gastroepiploic artery	
FNC*		Aorto-coronary venous bypass	
FND*		Aorto-coronary bypass using prosthetic graft	
FNE*		Coronary bypass using free arterial graft	
FNF*		Coronary thrombendarterectomy	
FNG*		Expansion and recanalisation of coronary artery	
SKS[3] code		**Procedure**	
UXAC85[A-D]		Coronary arteriography	
UXCC00A		Coronary computed tomography angiography	
SHAK[4] code		**Hospital**	
1301		Rigshospitalet	
1309		Bispebjerg og Frederiksberg Hospitaler	
1330		Amager og Hvidovre Hospital	
1351		Amager Hospital	
1401		Frederiksberg Hospital	
1501		Gentofte Hospital	
1502		Glostrup Hospital	
1516		Herlev og Gentofte Hospital	
2000		Hospitalerne i Nordsjælland	
2501		Amtssygehuset i Roskilde	
3800		Region Sjællands Sygehusvæsen	
4001		Bornholms Hospital	

[1] ICD-10 = WHO International classification of diseases and health related problems 10th edition. Danish version where code types A, B and G included in our definition of primary and secondary codes.
[2] NOMESCO = Nordic Medico-Statistical Committee
[3] SKS = Sundhedsstyrelses klassifikationsstystem [danish]
[4] SHAK = Sygehus- og afdelingsklassifikation [danish]
[*] Included in the composite outcome new ischemic events. For ICD-10 codes only code types A (primary) and in-hospital patients.

S1 Appendix: ***MCL algorithm settings and assessment of cluster robustness***

To define the patient similarity network, a lower rank approximation of the matrix was created using the "truncatedSVD" implementation of SVD from the python package scikit-learn with 41 components, 10 iterations, and fixed random seed of 42 to ensure reproducible results. By selecting 41 components, the accumulated explained variance ratio was 0.50 (S2 Fig). To reduce the density of the patient similarity network, while still retaining an informative topology, all edges with an edge weight less than 0.3 were removed and the number of edges connected to each node were limited using the "#ceilnb" transformation from "mcl-edge"; a maximum of 8000 was used (S3 Fig). The weights of the remaining edges in the network were shifted such that the lowest weight was 0.0 as recommended in the MCL manual. The final pre-processed networks were then used as input for the "mcl" implementation of the MCL algorithm(1). We used a pruning scheme of -P 7000 -S 800 -R 900 -pct 90, and a pre-inflation factor of 0.5 to make edge-weights more homogenous. For the MCL clustering, we selected a pre-inflation parameter of 2.0 corresponding to the default in the MCL manual(2).

For cluster robustness assessment, diluted versions of the reference clustering were generated by deleting edges with a probability of α, where α would range between 0 and 50%(3). An α of 0 would leave the network unchanged. In contrast, the shuffled versions of the network had the same number of nodes and edges as the reference clustering. The shuffled networks were generated as described by Karrer et al(4). Finally, the generated clusters were compared to the reference clustering and the variances were quantified with reference to the so-called variation of information measure (VI)(5).



S2 Fig: Selection of number of components. X-axis: Component number ranked by explained variance ratio. Y-axis: Explained variance ratio. Dashed horizontal line indicates the cutoff.



S3 Fig: Limiting edge-density and average node degree in sex-specific similarity networks. Mean/median number of neighbors against edge-weight cutoff in the patient similarity network. Only edges with a weight higher than 0.3 (as indicated by the vertical, dashed bar) were retained.

S2 Appendix: Preprocessing of laboratory data

The laboratory test results from the EHR data were originally archived in the administrative biochemical databases Labka and BCC(6). In relation to the EHR data used in this study, Labka covers the hospitals with SHAK codes 1301, 1309, 1330, 1351, 1401, 1501, 1516 and 4001 in the Capital Region of Denmark and BCC covers the hospitals with SHAK codes 2000 and 2501 in Region Zealand for the periods 2009-2016 and 2012-2016, respectively (S2 Table). Biochemical laboratory tests were either classified in accordance with the Nomenclature, Properties and Units (NPU) or local systems(7). Reference intervals were provided from the laboratories that analyzed the blood tests. Biochemical data was expected to be available for the patients where the index procedure was performed at a hospital located in either the Capital Region or Region Zealand at a time that was covered by the two databases.

S2 Table: Laboratory codes included in assessment of data quality and completeness

Blood analyte	NPU codes and local systems
Sodium	NPU03429, GEN00992, NPU03796, POC00022, 240, POC00021, POC00023, GEN00990
Potassium	NPU03230, GEN00995, POC00019, POC00018, POC00020, GEN00993
Hemoglobin	NPU02319, GEN00989, NPU02321, NPU02320, NPU02322, NPU17007, POC00013, NPU04208, NPU01393, POC00012, POC00014, NPU29057, GEN00987
Creatinine / EGFR	NPU04998, NPU03918, NPU09102, NPU19661, NPU14048, NPU03800, HLL00037, DNK35131, POC00109, RHB00941, NPU28842

A total of 48,957 patients (30,736 males and 18,221 females) were included from a hospital where biochemical data was available (67.8% of the entire cohort). As an indicator for data completeness and quality, the number of patients where available biochemical data at time of index agreed with the clinical standard of care was assessed. This implied that patients had sodium, potassium, hemoglobin, and creatinine (or estimated glomerular filtration rate) measured maximum 90 days before or at the day of index. The 31,224 patients who fulfilled this requirement were included in the biochemical analysis. Laboratory measurements available for at least 50% of these patients were included in the analysis. In cases where patients had more than one test available in the period up from 90 days before to index, the test closest to index was used. As listed in the main text included samples were plasma levels of potassium, sodium, hemoglobin, estimated glomerular filtration (eGFR), creatinine, carbamide, glucose, troponin (I/T), HDL cholesterol, LDL cholesterol, total cholesterol, leukocytes, C-reactive protein, lymphocytes, monocytes, neutrophils, basophils, platelets, INR, alanine transaminase, albumin, alkaline phosphatase, bilirubin, and triglyceride. All analyses of biochemical data were performed in R 3.6.2 using the “ComplexHeatmap” and “circlize” packages .

S3 Appendix: Calculation of polygenetic risk scores for 14 traits

Polygenic risk scores were calculated using the LDpred2 framework, implemented in the R package bigsnpr (v1.11.6) with R version 4.0.0 and the workflow management system Snakemake(11–13). In preparation for PGS calculations, autosomal genotype data from 242,644 individuals in the Copenhagen Hospital Biobank – Cardiovascular Disease Cohort (CHB-CVDC)(14) was filtered to only include variants present in LDpred2's recommended set of 1,054,330 reference variants. This recommended set is based on the reference set HapMap3 from the International HapMap project, which was established by genotyping 1.6 million single nucleotide polymorphisms (SNPs) in 1,184 individuals from 11 global populations(15). Any missing genotype information was assumed to be the affected locus' reference allele.

We matched the remaining set of 994,643 genotyped variants with variants found in summary statistics data corresponding to 14 traits, obtained from nine GWAS meta-analyses (atrial fibrillation(16), BMI-adjusted type 2 diabetes(17), chronic kidney disease(18), HDL cholesterol levels(19), heart failure(20), LDL cholesterol levels(19), stroke(21), total cholesterol levels(19), triglyceride levels(19)) and five GWAS (acute myocardial infarction(22), coronary artery disease(23), diastolic blood pressure(24), non-alcoholic fatty liver disease(25), systolic blood pressure(24)). Variants present in both genotype and summary statistics data were then subject to LDpred2's recommended standard deviation quality control. After variant matching and quality control, a mean of 963,354 (S.D. 87,774) variants remained for subsequent per-chromosome risk score calculation for each of the 14 traits. We used the LDpred2-auto algorithm with 30 Gibbs sampling chains, 1,000 burn-in iterations and 500 iterations after burn-in. The initial values for the 30 sampling chains were a) the LDSC regression estimate for heritability h^2 (same for all chains); b)

one of 30 initial values for the proportion of causal variants *p*, evenly spaced on a logarithmic scale from 10^{-4} to 0.5.

Variant effect sizes were calculated from each set of 30 sampling chains (per trait and chromosome) through a three-step process, which serves to ensure that the model (spanning 30 chains) successfully converged: 1) computing the standard deviations of each chains' predicted scores, 2) keeping only the chains within three median absolute deviations from the median standard deviation, 3) averaging the effect sizes of the remaining chains. Across the 308 per-chromosome models (14 traits times 22 chromosomes), 28.9 chains were included in the final score on average. For each individual, we calculated per-chromosome risk scores by multiplying the average variant effect sizes with the individual's corresponding genotype, and then added the per-chromosome risk scores up into one genome-wide PGS. To ease comparisons across traits, each trait's PGS distribution was scaled to a mean of zero and a standard deviation of one.

References, S1-3 Appendices

1. Van Dongen SM. Graph clustering by flow simulation. 2000.

2. MCL - a cluster algorithm for graphs [Internet]. [cited 2023 Jan 30]. Available from: http://micans.org/mcl/

3. Kirk IK, Simon C, Banasik K, Holm PC, Haue AD, Jensen PB, et al. Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. Valencia A, Barkai N, editors. eLife. 2019 Dec 10;8:e44941.

4. Karrer B, Levina E, Newman MEJ. Robustness of community structure in networks. Phys Rev E. 2008 Apr 29;77(4):046119.

5. Meilă M. Comparing clusterings—an information based distance. J Multivar Anal. 2007 May;98(5):873–95.

6. Grann AF, Erichsen R, Nielsen AG, Frøslev T, Thomsen RW. Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol. 2011 Apr 1;3:133–8.

7. Petersen UM, Dybkaer R, Olesen H. Properties and units in the clinical laboratory sciences. Part XXIII. The NPU terminology, principles, and implementation: A user's guide (IUPAC Technical Report)*. Pure Appl Chem. 2012;84(1):137–65.

8. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2019. Available from: https://www.R-project.org/

9. Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R. Bioinformatics. 2014 Oct 1;30(19):2811–2.

10. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016 Sep 15;32(18):2847–9.

11. Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al. Sustainable data analysis with Snakemake [Internet]. F1000Research; 2021 [cited 2023 Mar 16]. Available from: https://f1000research.com/articles/10-33

12. Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinformatics. 2020 Dec 1;36(22–23):5424–31.

13. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/

14. Sørensen E, Christiansen L, Wilkowski B, Larsen MH, Burgdorf KS, Thørner LW, et al. Data Resource Profile: The Copenhagen Hospital Biobank (CHB). Int J Epidemiol. 2021 Jun 1;50(3):719–720e.

15. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. Nature. 2010 Sep;467(7311):52–8.

16. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018 Sep;50(9):1234–9.

17. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018 Nov;50(11):1505–13.

18. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019 Jun;51(6):957–72.

19. Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, et al. The impact of low-frequency and rare variants on lipid levels. Nat Genet. 2015 Jun;47(6):589–97.

20. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020 Jan 9;11(1):163.

21. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018 Apr;50(4):524–37.

22. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021 Nov;53(11):1616–21.

23. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ Res. 2018 Feb 2;122(3):433–43.

24. Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok PY, et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. Nat Genet. 2017 Jan;49(1):54–64.

25. Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆. J Hepatol. 2020 Sep 1;73(3):505–15.

S3 Table: Comparison of mean age at index in 31 cluster using Tukey's HSD

See file S3Table.pdf.

S4 Table: Demographics for patients not cluster or were in clusters of size < 500

Cohort demographics	**Total**	**Males**	**Females**
Number of patients	5,113	3,878	1,235
Mean age at index (SD)	60.7	60.0	63.0
Outcomes, number of cases	**Total**	**Males**	**Females**
New ischemic events	995	780	175
Death from non-IHD causes	352	274	78
Censored	3,624	2,707	917
Outcomes, time to event	**Mean time to event in years (SD)**		
	Total	**Males**	**Females**
New ischemic events	1.55 (1.41)	1.59 (1.43)	1.39 (1.32)
Death from non-IHD causes	2.25 (1.50)	2.18 (1.47)	2.5 (1.49)
Censored	4.54 (0.95)	4.52 (0.96)	2.47 (1.49)
Total	4.02 (1.52)	3.98 (1.54)	4.17 (1.44)

S5a Table: Degree of enrichment (sum) and top-10 O/E-ratios per cluster

S5 Table: Bottom-10 O/E-ratios < 1 per cluster

See file S5Table.pdf

S6 Table: Chi-squared test for distribution laboratory values in clusters

Component	**P-val.**	**Adj. P-val.**
Alanine transaminase (ALAT)	4.78 e-22	1.15e-20
Albumin	4.81e-22	1.15e-20
Alkaline phosphatase	2.01e-22	4.82e-21
Bilirubin	1.09e-13	2.60e-12
C-reactive protein (CRP)	1.65e-96	3.95e-95
Carbamide	5.49-e200	1.32e-198
Cholesterol HDL	1.99e-66	4.77e-65
Cholesterol LDL	4.86e-53	1.17e-51
Cholesterol total	2.64e-58	6.34 e-57
Coagulation factor II + VII + X	7.96e-280	1.91e-278
Creatinine	9.28e-302	2.23e-300
Eosinophils	4.43e-6	1.06e-4
Estimated glomerular filtration rate (eGFR)	0	0
Glucose	0	0
Hemoglobin	2.77e-218	6.65e-217
Leukocytes	1.42e-39	3.41e-38
Lymphocytes	1.54e-17	3.69e-16
Monocytes	1.06e-11	2.55e-10
Neutrophils	5.69e-20	1.36e-18
Platelets	2.39e-23	5.73e-22
Potassium	9.03e-32	2.17e-30
Sodium	2.24e-74	5.38e-74
Triglyceride	2.10e-60	5.04 e-59
Troponin	7.10e-73	1.70e-71

S7 Table: Traits with significantly different PGS distributions in clusters

Cluster	n	trait	effect	effect size	FDR
C1	2,025	Systolic Blood Pressure	+	0.20	<0.0005
		Diastolic Blood Pressure	+	0.16	<0.0005
		Total Cholesterol	-	-0.08	0.026
C4	1,532	Atrial Fibrillation	+	0.57	<0.0005
		Heart Failure	+	0.08	0.031
		Coronary Artery Disease	-	-0.12	0.001
		T2D (BMI-adj.)	-	-0.11	0.001
		Acute Myocardial Infarction	-	-0.08	0.031
		Triglyceride	-	-0.08	0.044
		Total Cholesterol	-	-0.08	0.046
C5	1,136	T2D (BMI-adj.)	+	0.55	<0.0005
		NAFLD	+	0.11	0.021
C6	860	Total Cholesterol	+	0.21	<0.0005
		Triglyceride	+	0.20	<0.0005
		LDL Cholesterol	+	0.15	0.001
		Coronary Artery Disease	+	0.15	0.001
		Diastolic Blood Pressure	-	-0.13	0.015
		Systolic Blood Pressure	-	-0.11	0.040
C8	817	Systolic Blood Pressure	-	-0.16	0.001
		Stroke	-	-0.12	0.023
		Coronary Artery Disease	-	-0.12	0.028
		Diastolic Blood Pressure	-	-0.11	0.031
		LDL Cholesterol	-	-0.10	0.047
C10	744	Coronary Artery Disease	-	-0.13	0.017
		Acute Myocardial Infarction	-	-0.13	0.021
C11	718	Stroke	-	-0.11	0.040
		Heart Failure	-	-0.11	0.040
C12	649	Coronary Artery Disease	-	-0.14	0.013
		Acute Myocardial Infarction	-	-0.12	0.033
C13	606	Diastolic Blood Pressure	-	-0.12	0.040
C15	588	LDL Cholesterol	+	0.14	0.020
		Total Cholesterol	+	0.14	0.026
C17	348	Systolic Blood Pressure	+	0.16	0.040
C18	481	T2D (BMI-adj.)	+	0.15	0.023
		Acute Myocardial Infarction	+	0.15	0.028
		Atrial Fibrillation	-	-0.13	0.049
C23	290	T2D (BMI-adj.)	+	0.27	0.001
C25	297	Coronary Artery Disease	+	0.24	0.002
		Acute Myocardial Infarction	+	0.18	0.032
		Heart Failure	+	0.18	0.031
C27	231	Stroke	+	0.24	0.015



Supplementary figure 4: Heatmap of clusters based on laboratory profiles. Summary of results from the phenotypic characterization of clusters based on laboratory data. *Score* refers to the mean summarized values per cluster, where values were assigned based on the results of the laboratory test per patient. Values of -1, 0, and 1, indicates below, within or above reference range, respectively. For details, see Methods. X-axis: Blood test analyte. Y-axis: Cluster.